Contraception
Volume 53, Issue 1 , Pages 41-47 , January 1996

Can grapefruit juice influence ethinylestradiol bioavailability?

  • A. Weber

      Affiliations

    • Department of Clinical Pharmacology Jena, Germany
    • ,
  • R. Jäger

      Affiliations

    • Clinic of Gynaecology Jena, Germany
    • ,
  • A. Börner

      Affiliations

    • Institute of Clinical Chemistry Jena, Germany
    • ,
  • G. Klinger

      Affiliations

    • Clinic of Gynaecology Jena, Germany
    • ,
  • R. Vollanth

      Affiliations

    • Department of Medical Informatics Jena, Germany
    • ,
  • K. Matthey

      Affiliations

    • Friedrich Schiller University of Jena, Jena, Germany
    • Jenapharm GmbH, Jena, Germany
    • ,
  • A. Balogh

      Affiliations

    • Corresponding Author InformationName and address for correspondence: A. Balogh, Ph.D., M.D., Department of Clinical Pharmacology, Friedrich Schiller University, Bachstr. 18, 07740 Jena, Germany
    • Department of Clinical Pharmacology Jena, Germany

Received 1 June 1995 ,Revised 2 October 1995 ,Accepted 6 October 1995.

References 

  1. Bolt HM, Bolt M, Kappus H. Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinylestradiol in man. Acta Endocrinol. 1977;85:189–197
  2. Reimers D, Nocke-Fink L, Breuer H. Rifampicin and the “pill” do not go well together. Am Med Assoc. 1974;277:608–611
  3. Rogers SM, Back DJ, Stevenson PJ, Grimmer SFM, Orme ML'E. Paracetamol interaction with oral contraceptive steroids: increased plasma concentration of ethinylestradiol. Br J Clin Pharmacol. 1987;23:721–725
  4. Back DJ, Breckenridge AM, MacIver M, Orme ML'E, Purba HS, Rowe PH. Interaction of ethinylestradiol with ascorbic acid in man. J Br Med. 1981;282:1516
  5. Bolt HM, Kappus H, Bolt M. Effect of rimpacin treatment on the metabolism of oestradiol and 17α-ethinylestradiol by human liver microsomes. Eur J Clin Pharmacol. 1975;8:301–307
  6. Guengerich FP. Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs. Am J Obstet Gynaecol. 1990;63:2159–2163
  7. Back DJ, Bates M, Bowden A, Breckenridge AM, Hall MJ. The interaction of phenobarbital and other anticon-vulsants with oral contraceptive steroid therapy. Contraception. 1980;30:495–503
  8. Reimers D, Jezek A. Rifampicin und andere Antituber-kulostatika bei gleichzeitiger oraler Kontrazeption. Prax Pneumo. 1971;25:255–262
  9. Donley TG, Smith RF, Roy B. Reduced oral contraceptive effectiveness with concurrent antibiotic use: a protocol for prescribing antibiotics to women in childbearing age. Compendium Continuing Education Dentistry. 1990;11:392–396
  10. Back DJ, Breckenridge AM, Orme MLE. Clinically important adverse drug interactions. 1984;2:305–307
  11. Ahluwalia BS, Curry CL, Crocker CL, Verma PS. Evidence of higher ethynylestradiol blood levels in human hypertensive oral contraceptive users. Fertil Steril. 1977;28:627–630
  12. Stadel BV. Oral contraception and cardiovascular disease. New Eng J Med. 1981;305:612–618
  13. Back DJ, Breckenridge AM, Crawford FE. An investigation of the pharmacokinetics of ethinylestradiol in women using radioimmunoassay. Contraception. 1979;20:263–273
  14. Back DJ, Breckenridge AM, MacIver M, Orme ML'E, Purba HS. The gut wall metabolism of ethinylestradiol and its contribution to the pre-systemic metabolism of ethinylestradiol in human. Br J Clin Pharmacol. 1982;13:325–330
  15. Back DJ, Bates M, Breckenridge AM, Ellis A, Hall JM, MacIver M, et al. The in vitro metabolism of ethinylestradiol, mestranol and levonorgestrel by human jejunal mucosa. Br J Clin Pharmacol. 1981;11:275–278
  16. Back DJ, Madden S, Orme ML'E. Gastrointestinal metabolism of contraceptive steroids. Am J Obstet Gynecol. 1990;163:2138–2145
  17. Williams JG, Longcope C, Williams KIH. Metabolism of [4-3H] and [4-14C] 17α-ethinylestradiol-3 methyl ether (mestranol) by women. Steroids. 1975;25:343–354
  18. Bolt WH, Kappus H, Bolt HM. Ring A-oxidation of 17-ethinylestradiol in man. Acta Endocrinol. 1977;85:189–197
  19. Bolt HM, Kappus H, Remmer H. Studies on the metabolism of ethinylestradiol in vitro and in vivo: the significance of 2-hydroxylation and the formation of polar products. Xenobiotica. 1973;3:733–785
  20. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP2A2-dependent metabolism of caffeine in man. Br J Clin Pharmacol. 1993;35:431–436
  21. Merkel U, Sigusch H, Hoffmann A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol. 1994;46:175–177
  22. Bailey DG, Spence JD, Munoz C, Arnold MO. Interaction of citrus juice with felodipine and nifedipine. The Lancet. 1991;337:268–269
  23. Bailey DG, Arnold JMO, Strong HA, Munoz C, Spence JD. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther. 1993;54:589–594
  24. Soons PA, Vogels BAPM, Roosemalen MCM, Schoemaker HC, Uchida E, Edgar B, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991;50:394–403
  25. Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit juice—felodipine interaction: mechanism, predict-ability and effect of naringin. Clin Pharmacol Ther. 1993;53:637–642
  26. Schubert W, Cullberg G, Edgar B, Hedner T. Inhibition of 17β-estradiol metabolism by grapefruit juice in ovariectomized women. Maturitas. 1995;20:155–163
  27. Guengerich FP. Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs. Am J Obstet Gynecol. 1990;163:2159–2163
  28. Guengerich FP. Oxidation of 17α-ethinylestradiol by human liver cytochrome P-450. Mol Pharmacol. 1988;33:500–508
  29. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochrome P-450 in the intestinal mucosa of rats and man. Clin Invest. 1987;80:1029–1036
  30. Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentration of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol. 1993;36:457–459
  31. Pierpoint WS. Flavonoids in the human diet. In:  Cody V,  Middleton E,  Harborne JB editor. Plant flavonoids in biology and medicine: Biochemical, pharmacological and structure-activity relationships. Alan R Liss Inc; 1986;p. 125–140
  32. Fotherby K. Intrasubject variability in the pharmacokinetics of ethinylestradiol. Steroid Biochem Mol Biol. 1991;38:733–736
  33. Kuhnz W, Louton T, Back DJ, Michaelis K. Radioimmunological analysis of ethinylestradiol in human serum—Validation of the method and comparison with a gas chromatographic-mass spectrometric assay. Arzneimittel-Forschung/Drug Research 199;43:16.
  34. Kanarkowski R, Tornatore KM, D'Ambrosio R, Gardner MJ, Jusko WJ. Pharmacokinetics of single and multiple doses of ethinylestradiol and levonorgestrel in relation to smoking. Clin Pharmacol Ther. 1988;43:23–31
  35. Goldzieher JW, Dozier TS, de la Pena A. Plasma levels and pharmacokinetics of ethinyl estrogens in various populations. Contraception. 1980;21:1–16
  36. Bocker R, Kleingeist B, Eichhorn M, Lepper H. In vitro interaction of contraceptive steroids with human liver cytochrome P-450 enzymes. Adv Contracept. 1991;7:140–148
  37. Ball SE, Forrester M, Wolf CR, Back DJ. Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17-ethinylestradiol. Biochem J. 1990;267:221–226
  38. Miniscalco A, Lundahl J, Regardh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. Pharmacol Exp Therap. 1992;261:1195–1199
  39. Kuhnz W, Louton T, Humpel M, Back DJ, Zamah NM. Influence of high doses of vitamin C on the bioavail-ability and the serum protein binding of levonorgestrel in women using a combination oral contraceptive. Contraception. 1995;51:111–116
  40. Orme ML'E, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet. 1983;8:95–136
  41. Fotherby K, Akpoviroro J. Pharmacokinetics of ethinylestradiol in women from different populations. Contraception. 1981;23:487–496
  42. Guengerich FP. Polymorphins of cytochrome P-450 in humans. Trends Pharmacol Sci. 1989;10:107–109
  43. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel—Lack of prediction by the erythromycin breath test. Drug Metab Dispos. 1994;22:947–955
  44. Stadel BV, Sternthal PM, Schlesselman JJ, Douglas MB, Hall WD, Kaul L, et al. Variation of ethinylestradiol blood levels among healthy women using oral contraceptives. Fertil Steril. 1980;33:257–260

PII: 0010-7824(95)00252-9

Contraception
Volume 53, Issue 1 , Pages 41-47 , January 1996

Article Tools